Study of high-dose semaglutide up to 16 mg in T2D patients explores whether doses beyond current approvals provide additional metabolic and weight benefits.
Key findingStudy of high-dose semaglutide up to 16 mg in T2D patients explores whether doses beyond current app
What the researchers found
Study of high-dose semaglutide up to 16 mg in T2D patients explores whether doses beyond current approvals provide additional metabolic and weight benefits.
Why it matters
Relevant to peptide therapeutics.
The numbers in context
245 participants randomized. Semaglutide doses: 2 mg, 8 mg, 16 mg weekly (subcutaneous). All on metformin with BMI ≥27.
How the study worked
In publication.
Who was studied
Adults with type 2 diabetes, BMI ≥27, on metformin
What this study cannot tell us
In publication.
How to read the evidence
Based on design.
When this study was published
Published in 2025.
The bigger picture
Advances peptide evidence.
Questions still open
- Long-term implications?
- Evidence comparison?
- Next steps?
Common questions
What does this mean?
How reliable?
Read the original research
High-Dose Semaglutide (Up to 16 mg) in People With Type 2 Diabetes and Overweight or Obesity: A Randomized, Placebo-Controlled, Phase 2 Trial.
Diabetes care, 48(6), 905-913
Citation
Aroda, Vanita R; Jørgensen, Nils B; Kumar, Bharath; Lingvay, Ildiko; Laulund, Anne Sofie; Buse, John B. (2025). High-Dose Semaglutide (Up to 16 mg) in People With Type 2 Diabetes and Overweight or Obesity: A Randomized, Placebo-Controlled, Phase 2 Trial.. Diabetes care, 48(6), 905-913. https://doi.org/10.2337/dc24-2425